NVIDIA-BACKED IAMBIC FILES FOR U.S. IPO HOURS AFTER ANNOUNCING ABBVIE AI DRUG DISCOVERY DEAL AI drug discovery company Iambic Therapeutics filed for a U.S. IPO Monday afternoon, just hours after announcing a multi-year collaboration with AbbVie $ABBV. The AbbVie partnership will use Iambic’s AI platform to develop small-molecule drugs across immunology, neuroscience and oncology. Its Enchant v3 model is trained across more than 6,000 molecular properties. Nvidia is already a major pre-IPO shareholder, holding about 9.6M Iambic shares before the offering. Nvidia has backed Iambic since at least 2024. J.P. Morgan, Jefferies, BofA Securities and Citigroup are leading the offering. No IPO size, price range or valuation has been disclosed yet.